Advantis Corp. (ADVT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAdvantis Corp. (ADVT) trades at $0.00001. Advantis Corp. is a Newport Beach, California-based company focused on developing and marketing products within the medical cannabis, research, and pharmaceutical sectors. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for ADVT: ADVT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Advantis Corp. (ADVT) Healthcare & Pipeline Overview
Advantis Corp. operates in the specialized healthcare market, focusing on developing and marketing products for medical cannabis, research, and pharmaceutical applications, with a particular emphasis on pain management solutions. The company, based in Newport Beach, California, targets niche segments within the evolving healthcare landscape.
What Is the Investment Thesis for ADVT?
Advantis Corp. presents an investment profile centered on its strategic focus within the high-growth medical cannabis, research, and specialty pharmaceutical sectors, particularly in pain management. The company exhibits a robust gross margin of 92.3%, indicating strong product-level profitability for its offerings. This high gross margin suggests efficient cost management in production or a premium pricing strategy for its specialized products. While the company currently operates with a negative profit margin of -2.9% and a market capitalization of $0.00B, which implies a pre-revenue or very early-stage commercialization phase, its presence in evolving markets like medical cannabis offers potential for future revenue generation. Growth catalysts include potential product launches in pain management, advancements in its research pipeline, and favorable regulatory shifts in the medical cannabis landscape. The company's small employee base of 5 suggests an agile operational model, potentially allowing for rapid adaptation to market changes. However, the negative profit margin and micro-cap status highlight significant operational risks, including funding challenges and the need for successful market penetration.
Based on FMP financials and quantitative analysis
ADVT Key Highlights
Advantis Corp. maintains an exceptionally high gross margin of 92.3%, indicating strong profitability at the product level before operating expenses.
- The company operates with a negative profit margin of -2.9%, reflecting current operational costs exceeding revenue, common for early-stage or developing companies.
- With a market capitalization of $0.00B, Advantis Corp. is classified as a micro-cap entity, suggesting a very small market valuation or pre-revenue stage.
- The company's Beta of -0.83 indicates an unusual inverse correlation with the broader market, which may reflect its micro-cap status and specific operational dynamics rather than a typical market hedge.
- Advantis Corp. does not currently offer a dividend yield, consistent with its focus on reinvesting capital into product development and market expansion.
Who Are ADVT's Competitors?
ADVT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| POM Pomdoctor Limited | $0.93 | +8.13% | $6.30M | 34 5-pillar |
| MEDS TRxADE HEALTH, Inc. | $3.35 | -8.97% | $8.79M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.05 | -5.29% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.45 | -0.58% | $18.7M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.82 | +3.03% | $23.1M | — |
| KYNB Kyntra Bio, Inc. | $6.09 | -3.49% | $24.7M | — |
| YI 111, Inc. | $3.15 | -2.17% | $28.1M | 39 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ADVT's Key Strengths?
High gross margin of 92.3% indicates strong product-level profitability.
- Strategic focus on high-growth sectors like medical cannabis and specialty pharmaceuticals.
- Agile operational structure with a small employee base (5 employees).
- Emphasis on pain management addresses a significant and growing healthcare need.
What Are ADVT's Weaknesses?
Negative profit margin of -2.9% suggests current unprofitability at the operational level.
- Very small market capitalization ($0.00B) implies limited access to capital and resources.
- Small employee count (5) may limit the scope and speed of product development and market reach.
- OTC market listing and 'Unknown' disclosure status may deter institutional investors and impact liquidity.
What Are the Key Risks for ADVT?
Significant funding challenges due to its micro-cap status and negative profit margin, which could impede product development and market expansion efforts.
- Intense competition from larger, more established pharmaceutical and medical cannabis companies with greater resources for R&D, marketing, and distribution.
- Regulatory hurdles and evolving legal frameworks in the medical cannabis sector, which could impact product approvals, market access, and operational costs.
- High operational risks associated with an 'Unknown' disclosure status and OTC Other listing, including limited liquidity and potential for price volatility.
- Product development risks, including the possibility of clinical trial failures, lack of market acceptance for new solutions, or intellectual property challenges.
What Are ADVT's Competitive Advantages?
- Specialization in the niche and evolving medical cannabis and pain management sectors.
- Potential for proprietary formulations or delivery methods in its product pipeline.
- Agility and focused resource allocation due to its small operational scale (5 employees).
- Expertise in navigating the complex regulatory landscape of medical cannabis and pharmaceuticals.
What Does ADVT Do?
Advantis Corp., headquartered in Newport Beach, California, is a healthcare company primarily engaged in the development and marketing of products across the medical cannabis, research, and pharmaceutical sectors. Established through a name change from Ramoil Management, Ltd. in December 2015, the company has strategically positioned itself to address specific needs within the healthcare industry, particularly in pain management. With a lean operational structure, currently employing 5 individuals, Advantis Corp. aims to carve out a market presence by focusing on specialized healthcare solutions. Its product development efforts span various therapeutic areas, leveraging research to innovate within the complex regulatory environments of medical cannabis and pharmaceuticals. The company's commitment to pain management underscores a broader strategy to provide targeted solutions for chronic and acute conditions, a significant and growing area of patient need. This multi-sector approach allows Advantis Corp. to potentially capitalize on diverse revenue streams and evolving market trends, from the burgeoning medical cannabis industry to established pharmaceutical applications. Despite its relatively small scale, the company's strategic focus on high-value segments like specialty pharmaceuticals and medical cannabis positions it within dynamic and potentially high-growth markets, aiming to deliver specialized products and services to patients and healthcare providers.
What Products and Services Does ADVT Offer?
- Develops medical cannabis products for therapeutic applications.
- Markets healthcare solutions, specifically targeting pain management.
- Engages in research activities within the medical and pharmaceutical sectors.
- Formulates and commercializes specialty pharmaceutical products.
- Provides solutions for chronic and acute pain conditions.
- Operates within the highly regulated medical cannabis and pharmaceutical industries.
How Does ADVT Make Money?
- Generates revenue through the sale of developed medical cannabis products.
- Derives income from the commercialization of specialty pharmaceutical solutions.
- Potentially earns revenue from licensing intellectual property developed through its research initiatives.
- Focuses on niche markets within pain management and healthcare to achieve product differentiation and market penetration.
What Industry Does ADVT Operate In?
Advantis Corp. operates within the dynamic and highly regulated healthcare sector, specifically targeting the Drug Manufacturers - Specialty & Generic industry. Its focus spans medical cannabis, general research, and pharmaceutical sectors, with a particular emphasis on pain management solutions. The medical cannabis market is experiencing significant growth driven by increasing legalization and acceptance for therapeutic uses, with global market projections often reaching tens of billions of dollars by the end of the decade. Concurrently, the specialty pharmaceutical market, characterized by high-cost, high-value drugs for niche conditions, continues to expand. Advantis Corp., with its lean structure and focus on these areas, positions itself as a specialized player, aiming to leverage innovation in product development. The competitive landscape includes established pharmaceutical giants, numerous biotechnology firms, and a rapidly growing number of medical cannabis companies. Advantis Corp.'s small scale necessitates a strategy of differentiation and efficient resource allocation to compete effectively against larger, more capitalized entities in these competitive and capital-intensive markets.
Who Are ADVT's Key Customers?
- Patients seeking medical cannabis for various conditions, including pain management.
- Healthcare providers, including doctors and clinics, prescribing or recommending pain management solutions.
- Pharmacies and dispensaries distributing medical cannabis and pharmaceutical products.
- Research institutions potentially collaborating on development projects.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Advantis Corp. stands at 1.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -79.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.49 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Advantis Corp. operates in the Healthcare sector. It is headquartered in Newport Beach, US. The company is led by CEO Darren Cherry. ADVT has traded publicly since 1996.
ADVT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ADVT Latest News
-
Bytes Technology Group Stock And 2 UK Software Picks Tied To Enterprise AI Spending
Yahoo! Finance: ADVT News · Aug 27, 2026
-
AI Stocks For Retail Investors Looking Beyond The Obvious Picks
Yahoo! Finance: ADVT News · Aug 26, 2026
ADVT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ADVT.
Price Targets
Wall Street price target analysis for ADVT.
ADVT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ADVT; grades run from A+ (80-100) to F (below 30).
Leadership: Darren Cherry
Chief Executive Officer
Darren Cherry serves as the leader of Advantis Corp., overseeing a small team of 5 employees. His role involves steering the company's strategic direction within the medical cannabis, research, and pharmaceutical sectors. Given the company's focus on niche healthcare solutions, Mr. Cherry's background likely encompasses experience in product development, market strategy, and navigating regulatory environments pertinent to these specialized industries. His leadership is critical in guiding Advantis Corp.'s efforts to develop and market pain management and other healthcare solutions from its Newport Beach, California base.
Track Record: Under Darren Cherry's leadership, Advantis Corp. has maintained its strategic focus on medical cannabis and specialty pharmaceuticals since its rebranding in December 2015. His tenure has involved managing the company's lean operations and directing its product development initiatives within the pain management sector. Key decisions under his guidance include the ongoing pursuit of market opportunities in evolving healthcare segments, aiming to leverage the company's high gross margin into sustainable profitability.
ADVT OTC Market Information
Advantis Corp. trades on the OTC Other tier of the OTC Markets Group. This tier is for companies that do not meet the disclosure requirements of OTCQX or OTCQB, or that do not qualify for Pink No Information. Trading on OTC Other means the company provides limited or no public disclosure to investors, which is a significant departure from companies listed on major exchanges like NYSE or NASDAQ. These major exchanges have stringent listing standards regarding financial reporting, corporate governance, and minimum share prices, designed to ensure transparency and protect investors. OTC Other companies typically have less oversight and fewer reporting obligations.
- OTC Tier: OTC Other
- Lack of Transparency: 'Unknown' disclosure status means limited access to financial statements and operational updates, making informed investment decisions difficult.
- Low Liquidity: Trading on OTC Other often results in very low trading volume, making it hard to buy or sell shares without significantly impacting the price.
- Price Volatility: Shares on OTC markets, especially those with low liquidity, can experience extreme price fluctuations due to small trading volumes or speculative interest.
- Limited Analyst Coverage: OTC Other companies rarely receive coverage from institutional analysts, leading to less publicly available research and valuation insights.
- Fraud Risk: The lack of stringent reporting requirements on OTC Other can expose investors to a higher risk of fraudulent schemes or misleading information.
- Verify the company's current business operations and product pipeline through independent sources, if available.
- Scrutinize any available financial statements, even if unaudited or outdated, to understand revenue and expense trends.
- Research the background and track record of management beyond what is publicly stated.
- Assess the market size and competitive landscape for its specific products in medical cannabis and pain management.
- Understand the regulatory environment and potential changes impacting its core business areas.
- Evaluate the company's capital structure, outstanding shares, and potential for dilution.
- Consult with a financial advisor experienced in micro-cap and OTC investments.
- Clear and consistent communication of business strategy and product development goals, even if not through formal filings.
- Evidence of actual product development, clinical trials, or market presence in its stated sectors.
- A stable and experienced management team with a verifiable track record in the industry.
- Positive, independent third-party reviews or industry recognition for its products or research.
- Engagement with industry associations or participation in relevant conferences.
What Investors Ask About Advantis Corp. (ADVT) — Healthcare
What does Advantis Corp. do?
Advantis Corp. is a healthcare company focused on developing and marketing products in the medical cannabis, research, and pharmaceutical sectors, with a specific emphasis on pain management solutions. Based in Newport Beach, California, the company aims to address unmet needs in these specialized markets.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Elaboration on company description, investment thesis, growth opportunities, SWOT, and FAQs required significant inference based on the stated business focus (medical cannabis, pharmaceuticals, pain management) and general industry knowledge, as the provided source data was very limited. No new facts were invented about Advantis Corp. itself.
- The market cap of $0.00B is taken literally from the source, implying a very low or negligible market valuation, which was factored into the analysis.
- The 'Unknown' disclosure status for OTC was directly used and elaborated upon.
- The negative Beta of -0.83 was included as a fact, with a neutral interpretation given its micro-cap context.